The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2020 | Venetoclax plus low-dose cytarabine in untreated older AML patients
Andrew Wei, MBBS, PhD, of Alfred Hospital and Monash University, Melbourne, Australia, updates us on the Phase III study of venetoclax plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (AML). Dr Wei further details an updated analysis of the phase Ib study with 3.5 years median follow-up also in untreated, older AML patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
